Top Cited Articles
Acceptance rate:
21%
Impact Factor (JCR):
10.3
IF rank (Oncology):
26/322
IF rank (Immunology):
12/181
Citescore:
17.7
Total content views:
987,869
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice
New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open- label, phase II trial
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases
Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies
YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial
Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors
Cell-free DNA approaches for cancer early detection and interception
Targeting Cbl-b in cancer immunotherapy
Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis